| Clinical data | |
|---|---|
| Other names | ACH-1625 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C43H53N5O8S |
| Molar mass | 799.98 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sovaprevir (codenamedACH-1625) is an experimental drug designed to treat thehepatitis C virus. It is underdevelopment byAchillion Pharmaceuticals. It acts as aNS3/4A inhibitor.[1] Sovaprevir receivedfast track status from the U.S.Food and Drug Administration in 2012.[2]
Thisantiinfectivedrug article is astub. You can help Wikipedia byadding missing information. |